{"accessLevel": "public", "bureauCode": ["020:00"], "contactPoint": {"fn": "Richard Judson", "hasEmail": "mailto:judson.richard@epa.gov"}, "description": "The files and .R scripts here are provided to aid in understanding and reproduction of the analyses in the submitted paper, \"Examining the Utility of In Vitro Bioactivity as a Protective Point of Departure: A Case Study.\"\nThe scripts in the .R folder reference source files in the other folders. \n\nThis dataset is associated with the following publication:\nFriedman, K., M. Gagne, L. Loo, P. Karamertzanis, T. Netzeva, T. Sobanski, J. Franzosa, A. Richard, R. Lougee, A. Gissi, J.J. Lee, M. Angrish, J. Dorne, S. Foster, K. Raffaele, T. Bahadori, M. Gwinn, J. Lambert, M. Whelan, M. Rasenberg, T. Barton-Maclaren, and R. Thomas. Utility of In Vitro Bioactivity as a Lower Bound Estimate of In Vivo Adverse Effect Levels and in Risk-Based Prioritization.   TOXICOLOGICAL SCIENCES. Society of Toxicology, RESTON, VA,  173(1): 202-225, (2020).", "distribution": [{"accessURL": "https://github.com/USEPA/-Examining-the-Utility-of-In-Vitro-Bioactivity", "title": "https://github.com/USEPA/-Examining-the-Utility-of-In-Vitro-Bioactivity"}], "identifier": "https://doi.org/10.23719/1503823", "keyword": ["ACToR", "Threshold of Toxicological Concern (TTC)", "high-throughput screening", "high-throughput toxicokinetics", "new approach methodologies", "point of departure (POD)"], "license": "https://pasteur.epa.gov/license/sciencehub-license.html", "modified": "2019-06-04", "programCode": ["020:095"], "publisher": {"name": "U.S. EPA Office of Research and Development (ORD)", "subOrganizationOf": {"name": "U.S. Environmental Protection Agency", "subOrganizationOf": {"name": "U.S. Government"}}}, "references": ["https://doi.org/10.1093/toxsci/kfz201"], "rights": null, "title": "KPF_Examining the Utility of In Vitro Bioactivity as a Protective Point of Departure: A Case Study_APCRA"}